Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis

Chafic Karam, Matthew J. Barrett, Theresa Imperato, Daniel J L Macgowan, Stephen Scelsa

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We studied 25-hydroxyvitamin D (vitamin D) levels in patients with amyotrophic lateral sclerosis (ALS) and the effect of vitamin D supplementation. Vitamin D levels were checked in 37 consecutive patients with ALS. Demographic data, vitamin D supplementation, change in Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score, and side effects from vitamin D were noted over a 9 month follow-up period. ALSFRS-R scores were compared between patients who took vitamin D and those who did not. The median age was 55 years and median time since symptom onset was 61 months. The mean vitamin D level was 22.3 ng/mL (normal range, 30-80 ng/mL). Eighty-one percent of patients had a vitamin D level lower than 30 ng/mL and 43% had a vitamin D level lower than 20 ng/mL. Twenty patients took 2000 international units of vitamin D daily. After adjustment for age and baseline vitamin D levels in a linear regression model, the ALSFRS-R score decline was smaller in patients taking vitamin D at 9 months (p = 0.02) but was not significantly different at 3 or 6 months. Median vitamin D levels rose from 18.5 to 31.0 ng/mL at 6 months in the group taking vitamin D. No side effects secondary to vitamin D supplementation were reported. Vitamin D supplementation at 2000 international units daily was safe over a period of 9 months and may have a beneficial effect on ALSFRS-R scores. Further studies are warranted to determine whether there is a benefit in vitamin D supplementation for all ALS patients.

Original languageEnglish (US)
Pages (from-to)1550-1553
Number of pages4
JournalJournal of Clinical Neuroscience
Volume20
Issue number11
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Vitamin D Deficiency
Amyotrophic Lateral Sclerosis
Vitamin D
Linear Models

Keywords

  • ALSFRS-R
  • Amyotrophic lateral sclerosis
  • Vitamin D

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

Cite this

Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. / Karam, Chafic; Barrett, Matthew J.; Imperato, Theresa; Macgowan, Daniel J L; Scelsa, Stephen.

In: Journal of Clinical Neuroscience, Vol. 20, No. 11, 11.2013, p. 1550-1553.

Research output: Contribution to journalArticle

Karam, Chafic ; Barrett, Matthew J. ; Imperato, Theresa ; Macgowan, Daniel J L ; Scelsa, Stephen. / Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. In: Journal of Clinical Neuroscience. 2013 ; Vol. 20, No. 11. pp. 1550-1553.
@article{9a131a15849b4c4db54c008da64892ee,
title = "Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis",
abstract = "We studied 25-hydroxyvitamin D (vitamin D) levels in patients with amyotrophic lateral sclerosis (ALS) and the effect of vitamin D supplementation. Vitamin D levels were checked in 37 consecutive patients with ALS. Demographic data, vitamin D supplementation, change in Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score, and side effects from vitamin D were noted over a 9 month follow-up period. ALSFRS-R scores were compared between patients who took vitamin D and those who did not. The median age was 55 years and median time since symptom onset was 61 months. The mean vitamin D level was 22.3 ng/mL (normal range, 30-80 ng/mL). Eighty-one percent of patients had a vitamin D level lower than 30 ng/mL and 43{\%} had a vitamin D level lower than 20 ng/mL. Twenty patients took 2000 international units of vitamin D daily. After adjustment for age and baseline vitamin D levels in a linear regression model, the ALSFRS-R score decline was smaller in patients taking vitamin D at 9 months (p = 0.02) but was not significantly different at 3 or 6 months. Median vitamin D levels rose from 18.5 to 31.0 ng/mL at 6 months in the group taking vitamin D. No side effects secondary to vitamin D supplementation were reported. Vitamin D supplementation at 2000 international units daily was safe over a period of 9 months and may have a beneficial effect on ALSFRS-R scores. Further studies are warranted to determine whether there is a benefit in vitamin D supplementation for all ALS patients.",
keywords = "ALSFRS-R, Amyotrophic lateral sclerosis, Vitamin D",
author = "Chafic Karam and Barrett, {Matthew J.} and Theresa Imperato and Macgowan, {Daniel J L} and Stephen Scelsa",
year = "2013",
month = "11",
doi = "10.1016/j.jocn.2013.01.011",
language = "English (US)",
volume = "20",
pages = "1550--1553",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "11",

}

TY - JOUR

T1 - Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis

AU - Karam, Chafic

AU - Barrett, Matthew J.

AU - Imperato, Theresa

AU - Macgowan, Daniel J L

AU - Scelsa, Stephen

PY - 2013/11

Y1 - 2013/11

N2 - We studied 25-hydroxyvitamin D (vitamin D) levels in patients with amyotrophic lateral sclerosis (ALS) and the effect of vitamin D supplementation. Vitamin D levels were checked in 37 consecutive patients with ALS. Demographic data, vitamin D supplementation, change in Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score, and side effects from vitamin D were noted over a 9 month follow-up period. ALSFRS-R scores were compared between patients who took vitamin D and those who did not. The median age was 55 years and median time since symptom onset was 61 months. The mean vitamin D level was 22.3 ng/mL (normal range, 30-80 ng/mL). Eighty-one percent of patients had a vitamin D level lower than 30 ng/mL and 43% had a vitamin D level lower than 20 ng/mL. Twenty patients took 2000 international units of vitamin D daily. After adjustment for age and baseline vitamin D levels in a linear regression model, the ALSFRS-R score decline was smaller in patients taking vitamin D at 9 months (p = 0.02) but was not significantly different at 3 or 6 months. Median vitamin D levels rose from 18.5 to 31.0 ng/mL at 6 months in the group taking vitamin D. No side effects secondary to vitamin D supplementation were reported. Vitamin D supplementation at 2000 international units daily was safe over a period of 9 months and may have a beneficial effect on ALSFRS-R scores. Further studies are warranted to determine whether there is a benefit in vitamin D supplementation for all ALS patients.

AB - We studied 25-hydroxyvitamin D (vitamin D) levels in patients with amyotrophic lateral sclerosis (ALS) and the effect of vitamin D supplementation. Vitamin D levels were checked in 37 consecutive patients with ALS. Demographic data, vitamin D supplementation, change in Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score, and side effects from vitamin D were noted over a 9 month follow-up period. ALSFRS-R scores were compared between patients who took vitamin D and those who did not. The median age was 55 years and median time since symptom onset was 61 months. The mean vitamin D level was 22.3 ng/mL (normal range, 30-80 ng/mL). Eighty-one percent of patients had a vitamin D level lower than 30 ng/mL and 43% had a vitamin D level lower than 20 ng/mL. Twenty patients took 2000 international units of vitamin D daily. After adjustment for age and baseline vitamin D levels in a linear regression model, the ALSFRS-R score decline was smaller in patients taking vitamin D at 9 months (p = 0.02) but was not significantly different at 3 or 6 months. Median vitamin D levels rose from 18.5 to 31.0 ng/mL at 6 months in the group taking vitamin D. No side effects secondary to vitamin D supplementation were reported. Vitamin D supplementation at 2000 international units daily was safe over a period of 9 months and may have a beneficial effect on ALSFRS-R scores. Further studies are warranted to determine whether there is a benefit in vitamin D supplementation for all ALS patients.

KW - ALSFRS-R

KW - Amyotrophic lateral sclerosis

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84886093910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886093910&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2013.01.011

DO - 10.1016/j.jocn.2013.01.011

M3 - Article

VL - 20

SP - 1550

EP - 1553

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 11

ER -